CAMP
CAMP4 Therapeutics Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.41
−1.78%Aug 13, 2026, 23:51 UTC
CAMP4 Therapeutics Corporation reported a Q2 2026 loss of $0.22 per share, beating the Zacks Consensus Estimate of a $0.24 loss and improving from a $0.62 loss a year earlier.
Source:Aug 6, 2026, 18:52 UTC
CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 clinical trial of CMP-002, an experimental ASO therapy for SYNGAP1-related disorders, in children aged 2 to 18.
Source:Aug 4, 2026, 11:00 UTC
CAMP4 Therapeutics announced the second closing of a $100 million private placement, with proceeds of $50.1 million to support advancement of CMP-002 for SYNGAP1-related disorder.
Source:Jul 27, 2026, 11:00 UTC
CAMP4 Therapeutics received clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder.